The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis
| Autor: | Mio Ueda, Minako Akiyama, Shinnichi Iwai, Miho Nagai, Eiichiro Kanda, Yume Nagaoka, Yoshihiko Kanno, Michio Nagaoka, Rie Suzuki, Kakei Ryu, Yoshitaka Miyaoka, Yoshiko Tanaka, Hiroshi Yoshimoto |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class medicine.medical_treatment 030232 urology & nephrology Allopurinol 030204 cardiovascular system & hematology medicine.disease_cause Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Adverse effect Xanthine oxidase inhibitor Dialysis business.industry Hematology Topiroxostat chemistry Mechanism of action Nephrology Hemodialysis medicine.symptom business Oxidative stress medicine.drug |
| Zdroj: | Hemodialysis International. 22:388-393 |
| ISSN: | 1492-7535 |
| Popis: | Introduction: Topiroxostat, a recently developed xanthine oxidase inhibitor, is expected to have fewer adverse effects than allopurinol because it has different mechanism of action from alloprinol. However, its dosage, usage and safety have not been established in patients with impaired renal function or those undergoing dialysis at the development since no studies was conducted in these patients. Methods: Cross over clinical trial using 3 months of allopurinol and topiroxostat on 27 maintain Japanese HD patients were carried out. The effects on oxidative stress status of both drugs were also evaluated by measuring oxidation reduction potential. Findings: Twenty-five of twenty-seven patients completed study. The mean serum uric acid levels in the topiroxostat-treated arm was significantly lower than it in the allopurinol-treated arm time-dependently (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text